Literature DB >> 24248100

Objectifying the conjunctival provocation test: photography-based rating and digital analysis.

S Dogan1, A Astvatsatourov, T M Deserno, F Bock, K Shah-Hosseini, A Michels, R Mösges.   

Abstract

BACKGROUND: Patients with allergic rhinoconjunctivitis are susceptible to both nasal and ocular symptoms. The conjunctival provocation test (CPT) is an established diagnostic procedure used in allergic rhinoconjunctivitis, particularly to document a patient's current reactivity to allergens. To date, there are no international guidelines defining the CPT. No approved evaluation method exists for interpreting CPT results. This paper aims to establish the digital analysis of macroimages as an objective, validated and standardized method for interpreting CPT results.
METHODS: In a clinical immunotherapy trial with 155 patients, treatment progress was documented based on the CPT. Local investigators used a symptom score to grade tearing, reddening and the patients' subjective perception of symptoms (mucosal irritation). A central observer rated conjunctival hyperemia via digital photography. Digital image analysis software was utilized to determine conjunctival hyperemia.
RESULTS: Spearman's correlation between the local investigators' and the central observer's ratings was r = 0.729 (p < 0.001); the percentage of total agreement was 48% (based on 739 photos). Digital image analysis (based on 48 photos) had a high percentage of total agreement with the central observer's ratings (69%) but a low percentage of total agreement with the investigators' ratings (38%). The corresponding correlations were r = 0.264 and 0.064, respectively.
CONCLUSION: Photography-based rating by a central observer may represent a valuable supplement to the local investigator's assessment for making an objective evaluation of CPT results. Digital image analysis possesses the potential of being an objective evaluation method compared to the wide-spread subjective evaluation by the investigators.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24248100     DOI: 10.1159/000355333

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

1.  Comparison between digital and optical microscopy: Analysis in a mouse gut inflammation model.

Authors:  Airton Pereira E Silva; Sylvia Maria Nicolau Campos; Isabelle Mazza Guimarães; Gerlinde Agate Platais Brasil Teixeira
Journal:  Biomed Rep       Date:  2017-07-21

2.  Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing.

Authors:  Anne-Nele Grzella; Sabine Schleicher; Kija Shah-Hosseini; Anatoli Astvatsatourov; Esther Raskopf; Silke Allekotte; Ralph Mösges
Journal:  Int Arch Allergy Immunol       Date:  2019-03-25       Impact factor: 2.749

3.  Validation of Computerized Quantification of Ocular Redness.

Authors:  Ekaterina Sirazitdinova; Marlies Gijs; Christian J F Bertens; Tos T J M Berendschot; Rudy M M A Nuijts; Thomas M Deserno
Journal:  Transl Vis Sci Technol       Date:  2019-12-12       Impact factor: 3.283

4.  Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  R Mösges; C Bachert; P Panzner; M A Calderon; L Haazen; S Pirotton; N Wathelet; S R Durham; M-A Bonny; T Legon; R von Frenckell; O Pfaar; M H Shamji
Journal:  Allergy       Date:  2018-06-21       Impact factor: 13.146

5.  Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients.

Authors:  R Mösges; A F Koch; E Raskopf; J Singh; K Shah-Hosseini; A Astvatsatourov; B Hauswald; Y Yarin; F Corazza; L Haazen; S Pirotton; S Allekotte; G Zadoyan; T Legon; S R Durham; M H Shamji
Journal:  Allergy       Date:  2018-02-13       Impact factor: 13.146

6.  A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients.

Authors:  C Hüser; P Dieterich; J Singh; K Shah-Hosseini; S Allekotte; W Lehmacher; E Compalati; R Mösges
Journal:  Allergy       Date:  2016-05-10       Impact factor: 13.146

7.  A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.

Authors:  R Mösges; E M Kasche; E Raskopf; J Singh; L Sohlich; A Astvatsatourov; K Shah-Hosseini; S Pirotton; L Haazen; S R Durham; T Legon; G Zadoyan; M H Shamji
Journal:  Allergy       Date:  2017-12-22       Impact factor: 13.146

8.  Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy.

Authors:  Janina Köther; Alicia Mandl; Silke Allekotte; Anatoli Astvatsatourov; Janin Chwieralski; Jan-Patrick Liedtke; Ursula Pieper-Fürst; Esther Raskopf; Kija Shah-Hosseini; Ralph Mösges
Journal:  Clin Transl Allergy       Date:  2018-07-04       Impact factor: 5.871

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.